Lung Cancer Clinical Trial
Official title:
Significance of Endoscopic Ultrasonography Guided Transbronchial Lymph Node Biopsy (TBNA) and Ultrasound Elastography in Lymph Node
Background and Objectives: Elastography can reflect the difference of tissue hardness, which helps to identify the difference of hardness between benign and malignant tissues. The aim of this study was to evaluate the value of endobronchial ultrasound elastography in the differential diagnosis of benign and malignant intrathoracic lymph nodes. Materials and Methods: A total of 42 patients with intrathoracic lymphadenopathy required for EBUS-TBNA examination were prospectively enrolled. Firstly, All patients were evaluated by enhanced chest CT examination,the EBUS B-mode ultrasound and EBUS‑guided elastography before EBUS-TBNA.Then, the investigators evaluated every lymph node by describing the characteristics of the CT image (Short diameter, texture, shape, boundary ,mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and elastography (image type, grading score, strain rate, blue area ratio). Finally, the pathological results were used as the gold standard. the investigators compare the characteristics of the 3 evaluating methods alone and in combination between benign and malignant lymph nodes.
Introduction Elastography was first proposed by Ophir of Texas State University in the United
States in 1991 ,which can objectively reflect the elastic information of the tissue through
the deformation of the external force. Then, the elastic information is converted to RGB
(red,green,blue) mode image, where hard tissue is shown in blue, medium tissue in green and
soft tissue in red, overlaid on the B-mode image. Different image colors reflect the
difference of tissue hardness, and then help identify the difference between benign and
malignant tissue hardness. UE has become a hot spot in medical ultrasound imaging shortly
after it was proposed. Now UE is widely used in the diagnosis of diseases in the breast,
thyroid, prostate and other related tissues. The common clinical UE includes quasi-static
elasiticity imaging, acoustic radiation force pulse (ARFI) and shear wave elastography (SWE).
Lung cancer is one of the most common malignancies with high morbidity and mortality,the
5-year survival rate being only 16%. Lymphatic metastasis, the most common mode of
metastasis, is of great significance for staging of lung cancer. Therefore, the correct
diagnosis of benign and malignant intrathoracic lymph nodes becomes the key to definite
diagnosis and accurate treatment. EBUS-TBNA has shown its certain diagnostic value in lung
cancer, lymphoma, sarcoidosis and lymph node tuberculosis. However, researches related to
real-time endobronchial UE (EBUS-RTE) are scarce, EBUS-RTE combined with EBUS B-mode
ultrasound and enhanced CT is even fewer.
This study aimed to evaluate the value of endobronchial UE in differentiating benign and
malignant intrathoracic lymph nodes qualitatively and quantitatively, and the combined
features were evaluated as well. Here we show that endobronchial UE has significant value in
the differential diagnosis of benign and malignant intrathoracic lymph nodes.
Materials and Methods Patients Patients undergoing EBUS-TBNA examination in the Department of
Respiratory Diseases, Nanjing Hospital Affiliated to Nanjing Medical University from June
2016 to April 2017 were recruited in this study. All patients were evaluated by chest
enhanced CT and/or 18-FDG PET-CT. Those who had enlarged intrathoracic lymph nodes(≥1cm)
and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation
function and serious cardiac dysfunction were finally selected. The study was approved by the
Ethics Committee of Nanjing Hospital (YL 20160713-020) and supported by Nanjing Science and
Technology Commission (201505002). All the patients gave written informed consent.
EBUS B-Mode ultrasound The patients were sedated by local anesthesia (lidocaine, China Otsuka
Pharmaceutical Incorporated Company) and conscious sedation (midazolam, Jiangsu Nhwa
Pharmaceutical incorporated company; fentanyl, Yichang Humanwell Pharmaceutical Incorporated
Company; and propyl chloride, Xi'an Libang Pharmacertical Company) .The patients received an
ultrasonic bronchoscopy (the Olympus 290 electronic bronchoscopy system of Japanese Olympus
Company) from the mouth, the glottis, through the trachea. The locations of the lymph nodes
were initially determined according to preoperative imaging examination. The B-mode
ultrasound was started and the image focus and depth of observation was adjusted after the
ultrasonic water sac was filled, so that the whole target lymph nodes and the surrounding
normal tissues were clearly displayed on the screen. the investigators observed multi
sections, selected the largest layer of the target lymph node, and retained pictures.The
ultrasound image characteristics were independently recorded by three skilled respiratory
physicians. The results were discussed and judged until consensus was reached.
EBUS UE The B-mode was switched to the elastography mode. When the image was stable, it would
be frozen and photographed. The observer judged the image type according to the color ratio
of the image. Type 1: mainly non-blue (green and red); type 2: partly blue, partly non-blue
(green and red); and type 3: mainly blue. Then, the strain rate ratios of normal tissue
(green and red) and the hardest region (the deepest blue) in the target lymph node region
were measured and recorded. In contrast to B-mode ultrasound lymph node images, the
elastography images were taken out as region of interest (ROI) in Image J software. The ROI
was converted into RGB encoding mode, and the blue part was extracted from the Metlab
software by setting the difference between the B component and the R and G components. After
that, the blue area to ROI area ratio was calculated. According to the blue area ratio, the
following grading standard was used to evaluate each lymph node as follows. 1 point: over 80%
of the section was non blue (green, yellow and red); 2 point: more than 50%, but less than
80% of the section was non-blue (green, yellow and red); 3 point: more than 50%, but less
than 80% of the section was blue; and 4 point: over 80% of the section was blue.
EBUS-TBNA and Final Diagnosis After elastography, switch to the blood flow pattern, avoid the
blood vessels, confirm the safe needle path to the target node and adjust the depth of the
needle (Cook Ireland Limited Liability Company, Ireland). EBUS-TBNA was performed under the
guidance of real-time ultrasound. Each target lymph node was punctured 3~4 times. All the
histological and cytological specimens were analyzed by pathologists who were blinded to the
elastography values. A positive diagnosis was confirmed by pathology and/or cytology, and all
patients with negative results underwent thoracoscopic or open chest surgery and follow-up to
confirm the benign and malignant lymph nodes.
Statistical Analysis All data statistics were analyzed by SPSS 22 (IBM, New York, USA)
statistical software. The normal distribution data were described by mean and standard
deviation, and the quantitative data were described by median (maximum and minimum), and the
qualitative data were described by percentage. All the numerical variables were analyzed by
one-way ANOVA, and the chi-square test was used for categorical variables. The difference was
statistically significant when P<0.05. If the benign and malignant group values conformed to
normal distribution and the variance was homogeneous, the independent sample t test was used,
otherwise the nonparametric test (Mann-Whitney test) was utilized. ROC analysis was conducted
to evaluate the diagnostic value of single characteristics and combined characteristics. The
maximum Youden index was calculated to determine the optimal cut-off point of differential
diagnosis of benign and malignant lymph nodes. The diagnostic accuracy, sensitivity,
specificity, PPV and NPV of each meaningful characteristic and combined characteristics were
calculated respectively.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|